EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1

Mikel García-Puga iD, Gorka Gerenu iD, Ariadna Bargiela iD, Jorge Espinosa-Espinosa iD, Laura Mosqueira-Martín iD, Maialen Sagartzazu-Aizpurua, Jesús M Aizpurua iD, Ainara Vallejo-Illarramendi iD, Rubén Artero iD, Adolfo López de Munain iD, Ander Matheu

Cells · 2024

DOI: 10.3390/cells13231939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Mikel García-Puga und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Oncology Group, Biogipuzkoa Health Research Institute, Paseo Dr. Beguiristain s/n, 20014 San Sebastian, Spain. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Aging, Premature, Fibroblasts, Phenotype. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carlos III Institute, University of the Basque Country, Juan de la Cierva-Incorporación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder clinically characterized by progressive muscular weakness and multisystem degeneration, which correlates with the size of CTG expansion and MBLN decrease. These changes induce a calcium and redox homeostasis imbalance in several models that recapitulate the features of premature tissue aging. In this study, we characterized the impact of a new family of FKBP12 ligands (generically named MPs or MP compounds) designed to stabilize FKBP12 binding to the ryanodine receptors and normalize calcium dysregulation under oxidative stress.

Methods

Human primary fibroblasts from DM1 patients and control donors, treated with MP compounds or not, were used for functional studies of cell viability, proliferation, and metabolism. The gene expression profile in treated cells was determined using RNA sequencing. The impact of MP compounds in vivo was evaluated in a Drosophila model of the disease using locomotor activity and longevity studies.

Results

The treatment with different MP compounds reversed oxidative stress and impaired cell viability and proliferation, mitochondrial activity, and metabolic defects in DM1-derived primary fibroblasts. RNA sequencing analysis confirmed the restoration of molecular pathways related to calcium and redox homeostasis and additional pathways, including the cell cycle and metabolism. This analysis also revealed the rescue of alternative splicing events in DM1 fibroblasts treated with MP compounds. Importantly, treatment with MP compounds significantly extended the lifespan and improved the locomotor activity of a Drosophila model of the DM1 disease, and restored molecular defects characteristic of the disease in vivo.

Conclusions

Our results revealed that MP compounds rescue multiple premature aging phenotypes described in DM1 models and decipher the benefits of this new family of compounds in the pre-clinical setting of DM1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyAging, PrematureFibroblastsPhenotypeTacrolimus Binding Protein 1AHumansAnimalsLigandsOxidative StressCell ProliferationCalciumCell SurvivalMaleDisease Models, Animal

Stichwörter der Autor:innen

FKBP12/RyR interactionextended longevitymultisystem recoverymyotonic dystrophyoxidative stress

Substanzen

LigandsTacrolimus Binding Protein 1ACalcium

Autor:innen und Institutionen

  • Cellular Oncology Group, Biogipuzkoa Health Research Institute, Paseo Dr. Beguiristain s/n, 20014 San Sebastian, Spain.
  • Neuroscience Area, Biogipuzkoa Health Research Institute, Biodonostia Institute, 20014 San Sebastian, Spain.
  • CIBERNED, CIBER, Carlos III Institute, 28029 Madrid, Spain.
  • Department of Health Sciences, Public University of Navarre (UPNA), Health Sciences Campus, Avda. de Barañain s/n, 31008 Pamplona, Spain.
  • IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain.
  • Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Spain.

ORCID-Profile: Mikel García-Puga, Gorka Gerenu, Ariadna Bargiela, Jorge Espinosa-Espinosa, Laura Mosqueira-Martín, Jesús M Aizpurua, Ainara Vallejo-Illarramendi, Rubén Artero, Adolfo López de Munain

Förderung

  • Carlos III Institute
  • University of the Basque Country
  • Juan de la Cierva-Incorporación
  • IKERBASQUE
  • Instituto Salud Carlos III and the European Union
  • Health department from Basque Country
  • Education department from Basque Country
  • PROMETEO/2020/081 project from the Generalitat Valenciana and CIBERNED funds

Zitieren

APA

García-Puga, M., Gerenu, G., Bargiela, A., Espinosa-Espinosa, J., Mosqueira-Martín, L., Sagartzazu-Aizpurua, M., Aizpurua, J. M., Vallejo-Illarramendi, A., Artero, R., López de Munain, A., & Matheu, A. (2024). A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1. Cells. https://doi.org/10.3390/cells13231939

Vancouver

García-Puga M, Gerenu G, Bargiela A, Espinosa-Espinosa J, Mosqueira-Martín L, Sagartzazu-Aizpurua M, et al. A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1. Cells. 2024. doi:10.3390/cells13231939

BibTeX
@article{GarcaPuga2024,
  author = {García-Puga, Mikel and Gerenu, Gorka and Bargiela, Ariadna and Espinosa-Espinosa, Jorge and Mosqueira-Martín, Laura and Sagartzazu-Aizpurua, Maialen and Aizpurua, Jesús M and Vallejo-Illarramendi, Ainara and Artero, Rubén and López de Munain, Adolfo and Matheu, Ander},
  title = {A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13231939}
}
Kostenlos starten →